Tian, Lei
Xiong, Xiaomo http://orcid.org/0000-0001-5657-5733
Guo, Qiang
Chen, Yixi
Wang, Luying
Dong, Peng
Ma, Aixia
Funding for this research was provided by:
Pfizer Investment Co. Ltd
Article History
Accepted: 31 August 2020
First Online: 15 September 2020
Declarations
:
: This study was funded by Pfizer Investment Co. Ltd (Beijing, China).
: Yixi Chen and Peng Dong are employees of Pfizer Investment Co. Ltd (Beijing, China). Lei Tian, Xiaomo Xiong, Qiang Guo, Luying Wang, and Aixia Ma have no conflicts of interest that are directly relevant to the content of this article.
: Not applicable.
: Not applicable.
: Not applicable.
: The authors declare that all data other than market shares of tumor necrosis factor inhibitors in the study are publicly available from the literature, conference abstracts, and governmental public sources as listed in the references section. The data of market shares of tumor necrosis factor inhibitors were provided by Pfizer Investment Co. Ltd (Beijing, China). The Excel models used for the analysis can be provided on reasonable request.
: Not applicable.